10 Best Mid Cap Pharma Stocks to Buy

8. Exact Sciences Corporation (NASDAQ:EXAS)

Market Capitalization as of July 22: $9.38 billion

Number of Hedge Fund Holders: 41

Exact Sciences Corporation (NASDAQ:EXAS) is one of the best mid cap pharma stocks to buy. On July 9, Exact Sciences announced that its Oncodetect molecular residual disease/MRD test received Medicare coverage. The coverage was granted through the Centers for Medicare & Medicaid Services’/CMS Molecular Diagnostic Services Program/MolDX for serial use in patients with stage II, III, and resectable stage IV colorectal cancer/CRC.

The coverage extends to both adjuvant and recurrence monitoring settings over 5 years. The Medicare coverage for colorectal cancer addresses a substantial need, as more than 3 million Americans are eligible for MRD testing across various solid tumors.

The Oncodetect test is a highly sensitive, tumor-informed assay that empowers oncologists and patients with critical insights throughout their treatment journey. It is capable of tracking up to 200 circulating tumor DNA/ctDNA)variants and can detect signs of cancer recurrence up to 2 years earlier than traditional imaging methods alone.

Exact Sciences Corporation (NASDAQ:EXAS) provides cancer screening and diagnostic test products in the US and internationally. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University.